// App-Quantinova.ai

2234 : Hydroxyurea Therapy Reduces The Hypercoagulability State In a Sickle Cell Mouse Model

Researchers

Presenter

  • Marina Pereira Colella

Principal Investigators

  • Camila Bononi Almeida

  • Nicola Conran

  • Flavia Rubia Pallis

  • Carla Fernanda Franco-Penteado

  • Joyce Maria Annichino-Bizzacchi

  • Fernando Ferreira Costa

  • Erich Vinicius de Paula

  • Sara Terezinha Olalla-Saad

  • Fabiola Traina

Medical Centers

  • Hematology and Hemotherapy Center - INCT do Sangue, University of Campinas - UNICAMP, Campinas, Brazil

  • Department of Internal Medicine, University of Sao Paulo at Ribeirao Preto School of Medicine, Ribeirao Preto, Brazil

  • INCT do Sangue, University of Campinas, Campinas, SP, Brazil

  • INCT do Sangue - Hematology and Hemotherapy Center, School of Medical Sciences, Brazil, University of Campinas - UNICAMP, Campinas, Brazil

  • Hematology and Hemotherapy Center, University of Campinas - UNICAMP, INCT do Sangue, Campinas, Brazil

  • Hematology and Hemotherapy Center-University of Campinas/Hemocentro-Unicamp, Instituto Nacional de Cincia e Tecnologia do Sangue, Brazil, Campinas, Brazil

  • Hematology and Hemotherapy Center, University of Campinas - UNICAMP, INCT do Sangue, Campinas, Brazil

Locations

  • Brazil

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Sickle cell anemia

  • Venous thrombosis

  • Anemia

Biomarkers

  • Alpha-tubulin N-acetyltransferase 1

  • Interleukin 6

  • Soluble Vascular Cell Adhesion Molecule-1

Drug/Treatment

  • Hydroxyurea

  • Hydroxycarbamide

  • Interleukin

  • Hemostatic Solution

  • Evithrom

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved